Azalea Therapeutics recently reported on a mouse study focused on in vivo CAR-T therapy, showcasing the potential for precise gene editing in the engineering of CAR-T cells.
This approach could significantly alter the landscape of CAR-T therapy by potentially reducing costs and improving access for patients.
The implications of this study extend to the operational frameworks of cancer treatment, suggesting a shift towards more efficient therapeutic strategies.